Dandan Yin
YOU?
Author Swipe
View article: Retraction Note to: Long noncoding RNA GAS5 affects cell proliferation and predicts a poor prognosis in patients with colorectal cancer
Retraction Note to: Long noncoding RNA GAS5 affects cell proliferation and predicts a poor prognosis in patients with colorectal cancer Open
View article: Radiation-Resistant Bacteria: Potential Player in Sustainable Wastewater Treatment
Radiation-Resistant Bacteria: Potential Player in Sustainable Wastewater Treatment Open
Radioactive wastewater generated from nuclear energy, medical, and industrial sectors poses persistent ecological and health risks, necessitating the development of safe and sustainable treatment strategies. Compared with conventional phys…
View article: Repurposing Mercaptopurine Through Collateral Lethality to Treat Cancers with Somatic <i>RB1–NUDT15</i> Loss
Repurposing Mercaptopurine Through Collateral Lethality to Treat Cancers with Somatic <i>RB1–NUDT15</i> Loss Open
Somatic retinoblastoma 1 ( RB1 ) loss is prevalent across different cancer types and is enriched in treatment‐refractory tumors, such as castration‐resistant prostate cancer (CRPC) and small‐cell lung cancer, but cannot be considered as a …
View article: Figure S9 from MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer
Figure S9 from MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer Open
MYLK-AS1 enhances the stability of GLUD1 mRNA by directly binding to ILF3.
View article: Figure S6 from MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer
Figure S6 from MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer Open
METTL3-mediated post-transcriptional m6A modification contributes to the activation of MYLK-AS1 in TKI resistance of NSCLC.
View article: Figure S12 from MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer
Figure S12 from MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer Open
Experiments related to the assessment of the therapeutic potential of R162/MYLK-AS1 ASO in TKI resistance.
View article: Table S6 from MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer
Table S6 from MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer Open
The oncogenotype information of TKI resistant patients for the construction of PDX.
View article: Figure S4 from MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer
Figure S4 from MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer Open
C-Myc mediated transcriptional activation contributes to the activation of MYLK-AS1 in TKI resistance of NSCLC.
View article: Table S4 from MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer
Table S4 from MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer Open
mRNAs variation abundance (>=1.5-fold) in MYLK-AS1-knockdown PC9/GR cells.
View article: Figure S2 from MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer
Figure S2 from MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer Open
The effect of MYLK-AS1 expression on gefitinib resistance of NSCLC.
View article: Figure S8 from MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer
Figure S8 from MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer Open
MYLK-AS1 drives phase separation of ILF3 in PC9/OR.
View article: Table S3 from MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer
Table S3 from MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer Open
Oligonucleotides sequences summary.
View article: Table S5 from MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer
Table S5 from MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer Open
A list of top five potential MYLK-AS1-interacting protein candidates in PC9/GR cells based on RNA-protein pull-down assays and mass spectrometry analysis.
View article: Figure S1 from MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer
Figure S1 from MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer Open
The establishment of gefitinib-resistant cell lines, genomic alterations information of resistant patients, and the effect of MYLK-AS1 on the drug resistance of sensitive cells.
View article: Figure S7 from MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer
Figure S7 from MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer Open
MYLK-AS1 interacts with ILF3 to regulate TKI resistance in HCC827/GR and PC9/OR.
View article: Figure S3 from MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer
Figure S3 from MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer Open
The establishment of osimertinib-resistant cell lines, and the effect of MYLK-AS1 expression on osimertinib resistance of NSCLC in vitro and in vivo.
View article: Figure S10 from MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer
Figure S10 from MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer Open
MYLK-AS1 promotes TKI resistance of lung cancer by regulating GLUD1.
View article: Table S2 from MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer
Table S2 from MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer Open
Correlation between MYLK-AS1 expression and clinicopathological characteristics of 50 NSCLC patients.
View article: Figure S11 from MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer
Figure S11 from MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer Open
The c-Myc/METTL3/MYLK-AS1/ILF3/GLUD1 regulatory axis enhances mitochondrial glutamine metabolism.
View article: Data from MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer
Data from MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer Open
Acquired resistance to EGFR tyrosine kinase inhibitors (TKI) limits the efficacy of molecular targeted therapy in non–small cell lung cancer (NSCLC). Metabolic reprogramming is a hallmark of lung cancer that could contribute to TKI resista…
View article: Table S1 from MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer
Table S1 from MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer Open
The clinicopathological characteristics of patients in NG group and GR group.
View article: Movie S1 from MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer
Movie S1 from MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer Open
The quick rearrangement of ILF3 droplets. A time-lapse movie of droplets formed by ILF3 undergoes fusion event.
View article: Figure S5 from MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer
Figure S5 from MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer Open
METTL3 induces the expression of MYLK-AS1 and promotes TKI resistance.
View article: Early diagnosis and aggressive intervention in Vibrio vulnificus infection following live fish dorsal fin puncture: a case report
Early diagnosis and aggressive intervention in Vibrio vulnificus infection following live fish dorsal fin puncture: a case report Open
In this paper, we report a case of traumatic wound infection caused by dorsal fin puncture of live fish. A 69-year-old woman developed progressive swelling of her right pinky finger after being stabbed by the dorsal fin of a live fish. The…
View article: Clinical, genetic and functional perspectives on ATP-binding cassette subfamily B member 4 variants in five cholestasis adults
Clinical, genetic and functional perspectives on ATP-binding cassette subfamily B member 4 variants in five cholestasis adults Open
BACKGROUND ATP-binding cassette subfamily B member 4 (ABCB4 ) deficiency is associated with cholestatic liver disease primarily because of missense mutations, and many variants remain unidentified. Here, we validate the pathogenicity and m…
View article: 8q24 derived ZNF252P promotes tumorigenesis by driving phase separation to activate c-Myc mediated feedback loop
8q24 derived ZNF252P promotes tumorigenesis by driving phase separation to activate c-Myc mediated feedback loop Open
As a well-known cancer risk region, the 8q24 locus is frequently amplified in a variety of solid tumors. Here we identify a pseudogene-derived oncogenic lncRNA, ZNF252P, which is upregulated in a variety of cancer types by copy number gain…
View article: STK11 genetic alterations in metastatic EGFR mutant lung cancer
STK11 genetic alterations in metastatic EGFR mutant lung cancer Open
This study was conducted to investigate the relationship between STK11 genetic alterations and the outcomes of patients with metastatic EGFR mutant lung cancer. Clinical characteristics and genomic data were downloaded from the cBioPortal …
View article: Data from MNX1-AS1 Promotes Phase Separation of IGF2BP1 to Drive c-Myc–Mediated Cell-Cycle Progression and Proliferation in Lung Cancer
Data from MNX1-AS1 Promotes Phase Separation of IGF2BP1 to Drive c-Myc–Mediated Cell-Cycle Progression and Proliferation in Lung Cancer Open
c-Myc and E2F1 play critical roles in many human cancers. As long noncoding RNAs (lncRNA) are known to regulate various tumorigenic processes, elucidation of mechanisms of cross-talk between lncRNAs and c-Myc/E2F1-related signaling pathway…
View article: Multi-omics analysis reveals NNMT as a master metabolic regulator of metastasis in esophageal squamous cell carcinoma
Multi-omics analysis reveals NNMT as a master metabolic regulator of metastasis in esophageal squamous cell carcinoma Open
Metabolic reprogramming has been observed in cancer metastasis, whereas metabolic changes required for malignant cells during lymph node metastasis of esophageal squamous cell carcinoma (ESCC) are still poorly understood. Here, we performe…
View article: A multifunctional “three-in-one” fluorescent theranostic system for hepatic ischemia–reperfusion injury
A multifunctional “three-in-one” fluorescent theranostic system for hepatic ischemia–reperfusion injury Open
A single-component multifunctional fluorescent theranostic system (MB-Gly) for use during hepatic ischemia-reperfusion injury (HIRI) has been developed.